Know Cancer

or
forgot password


Phase 2
18 Years
N/A
Not Enrolling
Both
Non-Hodgkin's Lymphoma

Thank you

Trial Information

Inclusion Criteria


- Diagnosis of relapsed or refractory low-grade, CD20+, B-cell NHL * Received and
failed at least 1 prior regimen of chemotherapy * Rituximab-naive or received prior
rituximab in their last treatment (single agent or in combination with chemotherapy)
and demonstrated a time to progression of at least 12 months.

Type of Study:

Interventional

Study Design:

Primary Purpose: Treatment

Principal Investigator

MD

Investigator Role:

Study Director

Investigator Affiliation:

Amgen

Authority:

United States: Food and Drug Administration

Study ID:

20010138

NCT ID:

NCT00044902

Start Date:

Completion Date:

Related Keywords:

  • Non-Hodgkin's Lymphoma
  • Lymphoma
  • Lymphoma, Non-Hodgkin

Name

Location